The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours

被引:9
作者
Clement, Dominique S. V. M. [1 ,2 ,7 ]
van Leerdam, Monique E. [3 ,4 ]
Tesselaar, Margot E. T. [3 ]
Cananea, Elmie [1 ]
Martin, Wendy [1 ]
Weickert, Martin O. [5 ]
Sarker, Debashis [6 ]
Ramage, John K. [1 ]
Srirajaskanthan, Rajaventhan [1 ,2 ]
机构
[1] Kings Coll Hosp London, Inst Liver Studies, ENETS Ctr Excellence, Kings Hlth Partners, London, England
[2] Kings Coll Hosp London, Dept Gastroenterol, London, England
[3] ENETS Ctr Excellence, Netherlands Canc Inst, Dept Gastrointestinal Oncol, Amsterdam, Netherlands
[4] Leiden Univ, Dept Gastroenterol & Hepatol, Med Ctr, Leiden, Netherlands
[5] Univ Hosp Coventry & Warwickshire NHS Trust, ARDEN NET Ctr, ENETS Ctr Excellence, Coventry, England
[6] Guys & St Thomas Hosp, Dept Med Oncol, London, England
[7] Kings Coll Hosp London, Inst Liver studies, Denmark Hill, London SE5 9RS, England
关键词
gastroenteropancreatic neuroendocrine tumour; malnutrition; sarcopenia; somatostatin analogue; survival; CARCINOID-SYNDROME; PROGNOSTIC-FACTORS; FOLLOW-UP; VITAMIN-D; DIAGNOSIS; CANCER; NEOPLASMS; EPIDEMIOLOGY; DEFICIENCIES; GUIDELINES;
D O I
10.1111/jne.13376
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with neuroendocrine tumours located in the gastroenteropancreatic tract (GEP-NETs) and treatment with somatostatin analogues (SSA's) are at risk of malnutrition which has been reported previously evaluating weight loss or body mass index (BMI) only. The global leadership into malnutrition (GLIM) criteria include weight loss, BMI, and sarcopenia, for diagnosing malnutrition. These GLIM criteria have not been assessed in patients with GEP-NETs on SSA. The effect of malnutrition on overall survival has not been explored before. The aim of this study is to describe the presence of malnutrition in patients with GEP-NET on SSA based on the GLIM criteria and associate this with overall survival. Cross-sectional study screening all patients with GEP-NETs on SSA's for malnutrition using the GLIM criteria. Body composition analysis for sarcopenia diagnosis were performed. Bloods including vitamins, minerals, and lipid profile were collected. Overall survival since the date of nutrition screening was calculated. Uni- and multivariate Cox regression analysis were performed to identify malnutrition as risk factor for overall survival. A total of 118 patients, 47% male, with median age 67 years (IQR 56.8-75.0) were included. Overall, malnutrition was present in 88 patients (75%); based on low BMI in 26 (22%) patients, based on weight loss in 35 (30%) patients, and based on sarcopenia in 83 (70%) patients. Vitamin deficiencies were present for vitamin D in 64 patients (54%), and vitamin A in 29 patients (25%). The presence of malnutrition demonstrated a significantly worse overall survival (p-value = .01). In multivariate analysis meeting 2 or 3 GLIM criteria was significantly associated with worse overall survival (HR 2.16 95% CI 1.34-3.48, p-value = .002). Weight loss was the most important risk factor out of the 3 GLIM criteria (HR 3.5 95% CI 1.14-10.85, p-value = .03) for worse overall survival. A high percentage (75%) of patients with GEP-NETs using a SSA meet the GLIM criteria for malnutrition. Meeting more than 1 GLIM criterium, especially if there is weight loss these are risk factors for worse overall survival.
引用
收藏
页数:13
相关论文
共 73 条
[1]   MAGNESIUM-DEFICIENCY - PATHOPHYSIOLOGIC AND CLINICAL OVERVIEW [J].
ALGHAMDI, SMG ;
CAMERON, EC ;
SUTTON, RAL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 24 (05) :737-752
[2]   Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [J].
Arnold, R ;
Trautmann, ME ;
Creutzfeldt, W ;
Benning, R ;
Benning, M ;
Neuhaus, C ;
Jurgensen, R ;
Stein, K ;
Schafer, H ;
Bruns, C ;
Dennler, HJ .
GUT, 1996, 38 (03) :430-438
[3]  
Barrea L., 2018, NUTRIENTS, V10, P1
[4]   Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours [J].
Basuroy, Ron ;
Bouvier, Cathy ;
Ramage, John K. ;
Sissons, Maia ;
Kent, Alexandra ;
Srirajaskanthan, Raj .
NEUROENDOCRINOLOGY, 2018, 107 (01) :42-49
[5]  
Beaumont JL., PANCREAS, V41
[6]   Nutritional status and nutritional risk in patients with neuroendocrine tumors [J].
Borre, Mette ;
Dam, Gitte Aaroe ;
Knudsen, Anne Wilkens ;
Gronbaek, Henning .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (03) :284-292
[7]  
Bourdel-Marchasson I., PLOS ONE, V9:1-7
[8]   Professor Philip Hodge A Tribute [J].
Brown, John Michael ;
Colquhoun, Howard .
ARKIVOC, 2021, :1-12
[9]  
Caplin ME, 2014, NEW ENGL J MED, V371, P224, DOI [10.1056/NEJMoa1316158, 10.1056/NEJMc1409757]
[10]  
Cederholm T, 2019, CLIN NUTR, V38, P1, DOI [10.1016/j.clnu.2019.02.033, 10.1016/j.clnu.2018.08.002, 10.1002/jcsm.12383, 10.1002/jpen.1440]